surmount-1 trial tirzepatide obesity without diabetes once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Shifts in body mass index

(2.2) If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose

You should call your doctor if you experience: Palpitations lasting more than a few minutes or occurring frequently Chest pain, pressure, or discomfort Dizziness, fainting, or extreme fatigue Shortness of breath Irregular heartbeats that feel very fast or out of control Your doctor may check your heart health through tests such as an electrocardiogram (ECG), a Holter monitor, or blood tests to check electrolytes and thyroid function

The visit is usually anywhere between 30-60 minutes long based on the patient's history and concerns/questions

Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycemia